

# Weekly COVID-19 Breakthrough Infections Report

**Clark County, Nevada** 


### Date: January 31, 2023

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.

Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.


Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.



### Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations

Figure 2:Percentage of Cases among 12 Years and Older By Vaccination Status





	Overall
All	<i>N %</i> 129669 10
All Age (in years)	129009 10
Age (iii yeuis) 0-4	8
5-11	1566
12-17	5958
18-24	11069
25-49	56620 4
50-64	30899 24
65+	23549 1
65+ Gender	23549 1
	E6506 4
Male	56526 4
Female	72174 5
Unknown	969
Race/Ethnicity	
Hispanic	26744 2
White	41321 3
Black	10195
API	16600 1
AEA	450
Other	9222
Unknown	25137 1
Travel History	
Yes	5628
No	35615 2
Unknown	88426 6
Hospitalization	
Yes	3355
No	40200 3
Unknown	86114 6
Death	
Yes	1200
No	9971
Unknown	118498 9
Vaccine Type	
Pfizer	86695 6
Novavax	5
Unknown	1109
Moderna	34820 2
Janssen	7039
Emergen	1
Underlying Conditions	
Yes	19741 1
No	109928 8

### Table 1: Population Characteristics of COVID-19 Breakthrough Cases

## Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
874682	129669	1443492	468082	14825	32427



	Overall
	N %
All	3355 10
Age (in years)	
5-11	5 (
12-17	19
18-24	34
25-49	340 10
50-64	586 1 <sup>°</sup>
65+	2371 7
Gender	
Male	1823 54
Female	1528 40
Unknown	4 (
Race/Ethnicity	
Hispanic	419 12
White	1958 5
Black	377 1
API	329 10
AEA	17
Other	100
Unknown	155
Travel History	
Yes	142 4
No	1725 5
Unknown	1488 44
Death	
Yes	849 2
No	609 18
Unknown	1897 5
Vaccine Type	
Pfizer	1953 5
Unknown	83 2
Moderna	1069 32
Janssen	250
Underlying Conditions	
Yes	2422 72
No	933 2



	Overal	Ī
	N %	,
All	1200 10	0
Age (in years)		
25-49	36	3
50-64	145 1	2
65+	1019 8	5
Gender		
Male	722 6	0
Female	478 4	0
Race/Ethnicity		
Hispanic	131 1	1
White	808 6	7
Black	126 1	1
API	115 1	С
AEA	6	1
Other	10	1
Unknown	4	С
Hospitalization		
Yes	849 7	1
No	77	6
Unknown	274 2	3
Vaccine Type		
Pfizer	659 5	5
Unknown	27	2
Moderna	392 3	3
Janssen	122 1	0
Underlying Conditions		
Yes	691 5	8
No	509 4	2

### Table 4: Population Characteristics of COVID-19 Breakthrough Deaths

### **Table 5: Breakthrough Death Rates**

Fully Vaccinated	Vaccinated	Unvaccinated	Unvaccinated	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate
Population	Deaths	Population	Deaths		per 100K population
874682	1200	1443492	8075	137	559

\* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson & Johnson vaccine.



Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	2422	72
	No	933	28
Hypertension	Yes	1546	N/A
Immunocompromised	Yes	136	N/A
Chronic Heart Disease	Yes	725	N/A
Chronic Liver Disease	Yes	63	N/A
Chronic Kidney Disease	Yes	477	N/A
Diabetes	Yes	909	N/A
Neurologic/Neurodevelopmental	Yes	200	N/A
Chronic Lung Disease	Yes	640	N/A
Historically Healthy	Yes	292	N/A

### Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

#### Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	691	58
	No	509	42
Hypertension	Yes	444	N/A
Immunocompromised	Yes	50	N/A
Chronic Heart Disease	Yes	249	N/A
Chronic Liver Disease	Yes	25	N/A
Chronic Kidney Disease	Yes	187	N/A
Diabetes	Yes	265	N/A
Neurologic/Neurodevelopmental	Yes	60	N/A
Chronic Lung Disease	Yes	198	N/A
Historically Healthy	Yes	26	N/A

Notes:

\* White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

\* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

\* The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).